Home Latest Articles
Latest Articles
  • Haixia YANG, Ying WANG, Lili LIU, Wei ZHANG
    World Clinical Drug. 2025, 46(7): 693-697.
    Objective

    To evaluate the efficacy of estradiol/estradiol-dydrogesterone tablets in patients with cesarean scar pregnancy(CSP) undergoing uterine artery embolization(UAE) combined with curettage.

    Methods

    A randomized controlled study was conducted involving 66 patients with CSP admitted to gynecology department of our hospital from May 2023 to May 2024. The patients were randomized into an observation group(UAE+curettage+estradiol/estradiol-dydrogesterone tablets), and a control group(UAE+curettage), with 33 cases in each group. Perioperative indicators,β-human chorio-nic gonadotrophin(hCG) levels, time to menstrual recovery, oxidative stress markers[glutathione peroxidase(GSH-Px) and noradrenalin(NE)], and adverse reaction rates were statistically analyzed between the two groups.

    Results

    The hospitalization duration(6.80±1.35)d, vaginal bleeding time(7.40±3.15)d, blood loss(65.21±5.12)mL, and β-hCG normalization time(17.50±3.75)d in the observation group were all significantly better than those in the control group(P<0.05). Post-treatment, GSH-Px activity (49.11±2.42)U/L and NE levels(49.25±3.47)ng/mL improved more markedly in the observation group(P<0.05).

    Conclusion

    The use of estradiol/estradiol-dydrogesterone as an adjuvant therapy can optimize the clinical outcomes, accelerate recovery, and has good safety.

  • Jianhua SHI, Xiangmei DUAN, Mengju LV, Wenyong SHEN, Meihua YANG
    World Clinical Drug. 2025, 46(7): 698-701.
  • Renkang TAN, Chunli ZHANG, Qiaofang CHEN, Jie QIU, Weixin LIN
    World Clinical Drug. 2025, 46(7): 702-707.
    Objective

    To explore the effects and safety of remimazolam in combination with remifentanil for anesthesia during hysteroscopic surgery.

    Methods

    A total of 120 patients who underwent hysteroscopic surgery at our hospital from June 2022 to June 2024 were included, and were randomly divided into the control group(n=60) and the study group(n=60). The control group received remifentanil plus propofol for anesthesia, while the study group received remifentanil plus remimazolam. The hemodynamic parameters, anesthesia induction time, emergence time, orienting recovery time,satisfaction score, and adverse reactions of the two groups were compared.

    Results

    There were no differences in mean arterial pressure(MAP), heart rate(HR), and oxygen saturation(SpO2) between the two groups before anesthesia induction(T0) and at the end of surgery(T3)(P>0.05). The MAP and SpO2 values at 1 minute after induction(T1)and during cervical dilation(T2) were lower than T0 in both groups, with the study group being higher than those of the control group(P<0.05). The HR value at T1 and T2 were higher than T0 in both groups, with the study group being lower than the control group(P<0.05). The anesthesia induction time, emergence time and orienting recovery time were shorter than those in the control group(P<0.05). The satisfaction score in the study group was higher than that in the control group[(4.82±0.46) points vs. (4.13±0.37) points, P<0.05]. The incidence of adverse reactions in the study group was lower than that in the control group(8.33% vs. 21.67%, P<0.05).

    Conclusion

    The combination of remimazolam and fentanyl provides good anesthesia effects, which can effectively maintain hemodynamic stability of patients undergoing hysteroscopic surgery, and reduce emergence time and the incidence of adverse reactions.

  • Chunmei WANG, Yangyang WANG, Panpan DI
    World Clinical Drug. 2025, 46(7): 708-714.
    Objective

    To establish the evaluation criteria for the rational use of pentoxifylline injection in patients with cerebral infarction(CI) caused by cerebral artery stenosis, and to provide a basis for rational clinical drug use.

    Methods

    Based on the instructions of pentoxifylline injection, relevant guidelines for CI caused by cerebral artery stenosis, and previous literature, the evaluation criteria were formulated. The attribute hierarchy model(AHM) was used to evaluate 292 cases of cerebral artery stenosis CI discharged patients who treated with pentoxifylline injection in our hospital from March 2023 to August 2024.

    Result

    In the evaluation of the rationality of the results, The relative weights of the indicators,from largest to smallest, are indications(0.1545), dosage and administration(0.1360), contraindications(0.1199),adverse reactions(0.1087), solvent selection(0.1008), drug interactions(0.1002), course of treatment(0.0955),precautions(0.0932), and route of administration(0.0912). Five patients(1.71%) had cases of exceeding contraindications and not following the precautions. Among them, the total deduction score of the visiting department was 106.55 points, with the deduction score for contraindications accounting for 56.26% and the deduction score for precautions accounting for 43.74%. There were 287 cases(98.29%) with excellent case scores and 5 cases(1.71%) with qualified cases.Contraindications and precautions showed significant differences in the score comparison(P<0.001).

    Conclusion

    The use of AHM to evaluate the rationality of pentoxifylline injection in CI patients caused by cerebral artery stenosis has clinical value. The current medication regimens are generally in line with the norms, but improvements are still needed in the screening of contraindications and medication monitoring. It is suggested to optimize management through measures such as strengthening multi-disciplinary collaboration, improving the electronic system for medication contraindications, and enhancing the review of pharmacists' prescriptions and medication education.

  • Haibin ZHU, Yue WANG, Xiaolan LIAO, Tingting WU, Zicheng YU
    World Clinical Drug. 2025, 46(7): 715-719.

    Eplontersen is a novel ligand-coupled antisense oligonucleotide drug for the treatment of transthyretin amyloid polyneuropathy(ATTR-PN). Compared with inotersen, eplontersen has a lower dosage and a lower frequency of administration, while its safety is improved. This article reviewed the mechanism, clinical efficacy and safety of eplontersen in the treatment of ATTR-PN, aiming to provide a reference for clinical medication.

  • Ming ZHOU, Min LIU, Yuliang LV
    World Clinical Drug. 2025, 46(7): 720-723.

    Poria cocos polysaccharide is a medicinal substance derived from dried sclerotium, mycelium and fermentation broth of Poria cocos. It exhibits various biological activities, including anti-tumor, anti-inflammatory,antioxidant and antidepressive effects. Poria cocos polysaccharide is mainly used in clinical practice to treat malignant tumors, colitis and depression and other diseases. With the in-depth study of the anti-tumor mechanism of Poria cocos polysaccharides, researchers have found that it exerts anti-tumor effects through immune regulation, inhibition of tumor cell proliferation, anti-angiogenesis and genetic regulation, and is widely used in the treatment of liver cancer, lung cancer and breast cancer. This article will comprehensively and systematically summarize the latest mechanism of action of Poria cocos polysaccharides against tumors, providing basic data and theoretical basis for the clinical application of the anti-tumor effect of Poria cocos polysaccharides and the development of new drugs.

  • Fengsen ZHANG, Xieyu GAN, Chunyuan HE, Weichen ZHAO, Fang WANG, Facai WANG
    World Clinical Drug. 2025, 46(7): 724-729.

    Non-alcoholic fatty liver disease(NAFLD) is a liver disease caused by metabolic abnormalities. NAFLD causes structural damage, dysfunction of the liver and, in severe cases, multiple organ failure. At present, the global prevalence of NAFLD is on the rise, and there is an urgent need for safe and effective therapeutic drugs. The intestinal flora is a complex microbial ecosystem that interacts with various body tissues through an intricate network, and the metabolites it generates are closely related to NAFLD. The polysaccharides of traditional Chinese medicine have the potential to regulate inflammation, immune response and intestinal microbiota, which can improve NAFLD. This article reviewed the research progress of traditional Chinese medicine polysaccharides and intestinal flora in NAFLD, aiming to provide better therapeutic strategies for NAFLD.

  • Ying WU, Yuanqi WANG, Xiangyu LI
    World Clinical Drug. 2025, 46(7): 730-736.
  • Chunyan LI, Qian XU, Guangtao XIA
    World Clinical Drug. 2025, 46(6): 529-533.

    Ankylosing spondylitis(AS) is an autoimmune disease mainly characterized by chronic inflammation of the axial spinal joints, and its onset is significantly correlated with genetic markers such as human leukocyte antigen B27. AS has the characteristics of multi-system involvement and can cause extra-articular manifestations such as gastrointestinal dysfunction, renal damage and skin and mucosal lesions. The clinical treatment drugs for AS mainly include three categories: non-steroidal anti-inflammatory drugs, glucocorticoids and antirheumatic drugs for improving the condition. With the breakthrough of biological targeted therapy, biological agents such AS tumor necrosis factor inhibitors and interleukin-17 inhibitors have become a new paradigm for the treatment of AS. This paper systematically reviewed the latest research on AS biological agents combined with AS physical rehabilitation, exercise therapy and other non-pharmaceutical intervention methods, aiming to provide evidence-based basis for optimizing the comprehensive management plan of AS.

  • Xinyue XIE, Guangtao XIA, Wubin LIU
    World Clinical Drug. 2025, 46(6): 534-540.

    Systemic lupus erythematosus(SLE) is is a chronic autoimmune disease characterized by multi-system involvement. The disease recurs repeatedly, often accompanied by infections and organ damage, which seriously threaten the quality of life of patients. With the breakthroughs of molecular immunology research, important progress has been made in the targeted treatment strategies for SLE. Based on evidence-based medical evidence, this paper systematically reviewed current drug treatment regimens for SLE, mainly including the optimized application of traditional drugs, as well as the clinical value of innovative therapies such as biological agents like belimumab and telitacicept, and novel treatment approaches such as chimeric antigen receptor T-cell immunotherapy, in order to provide evidence-based basis for individualized treatment decisions.

News